to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
Are bioresorbable stents from one company better than another? Arterial Remodeling Technologies thinks so. The company boasts that its stents offer faster and smoother bioresorption and crack-free expansion.
A treatment for tinnitus is the goal of two Ohio University colleagues who were frustrated by the lack of options for those suffering from this hearing disorder. Read more to find out how this medical device differs from its competitors.
Medical device startups need to know when it’s worthwhile to make use of the pre-IDE process. The FDA review team can provide valuable insight to the medical business, but there are drawbacks, too. Read more to find out the pros and cons of the pre-IDE process.
I recently attended the 39th Annual Induction Ceremony for the National Inventors Hall of Fame. As it has been in years past, it was awe-inspiring and of significant historical interest.
A new biomedical endowment at Duke University will support a program that has already launched new healthcare businesses. Read more to find out about Duke’s successes in commercializing medical technology.
The venture capital climate improved in RTP in the first quarter, but biotech companies are still competing for dollars. Several RTP companies saw venture capital investment for development of pharmaceutical products and medical technologies. Read more to learn about the venture capital climate.
In medical business news, imaging software firm Riverain Medical hopes to boost sales of a product that helps detect lung cancer. The company’s technology allows radiologists to see behind ribs and clavicles to get a better view of pulmonary nodules. Read more about this company’s promising future.
As Genentech's Executive Vice President of Research and Early Development, Richard Scheller leads scientists discovering medicines that will significantly impact the lives of patients. In this candid interview, he describes the challenges of his industry, and outlines the required steps for developing products in a heavily regulated environment. Scheller also shares some personal learning curves faced when he elected to leave academic life for a new role in a commercial enterprise.
Bill Gross thrives on turning innovative ideas into pioneering companies. He serves as founder and CEO of Idealab, which started over 75 companies since 1996. In this stimulating lecture, he shares how Idealab continues to bring incredible ideas to market, and his personal insights on starting and running successful organizations. Gross also describes the work of eSolar, a spin-off company of Idealab that works to make solar energy cost-competitive in the global marketplace.
A basic guide to exporting from UNZ 7 Co.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.